Loading current stock analysis…
Loading current stock analysis…
India
As of 06 Nov 2026, 03:30 pm
As of 5 November 2026, Abbott India (NSE) has a market capitalization of ₹57,628.1 crore. The stock closed at ₹26,605 after opening at ₹27,210 on a turnover of ₹5.22 crore. Immediate resistance sits at ₹26,793 (0.71% above), while support is observed at ₹26,592 (0.05% below).
The stock is down -6.6% year-to-date and -9.4% over the past year. Short-term momentum shows a +4.9% gain over the last 10 days and +1.4% over the last month. However, the stock remains in a significant drawdown, with a current decline of -25.4% from its peak.
Daily charts show a bullish super-trend with strong upward directional movement (+DI: 27.9 vs -DI: 16.06). Conversely, weekly and monthly trends are bearish, with super-trends indicating downward pressure. This divergence suggests short-term buying interest against a longer-term downtrend.
Yes. In 2026, India's pharmaceutical sector is the best-performing equity segment, up 27% year-to-date. Analysts attribute this to resilient domestic demand and improving US margins. However, some caution that high valuations may limit further market-beating gains compared to other sectors.
As of 06 Nov 2026, 03:30 pm
Showing 3 of 6 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Upward price movement of 2.63 standard deviations recorded on 2026-10-28.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Latest complete financial results and comparative quarterly trends.
Recent market and company developments associated with Abbott India.
ICICI Securities has issued a 'Buy' recommendation for Abbott India with a target price of Rs 33,500. The article provides this specific investment advice from the brokerage firm regarding the listed entity.
India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors.
GIFT Nifty indicated a gap-up open for the Nifty50 index, surging 342 points to 24,311, as Brent crude prices slipped below $100 amid expectations of a faster resolution to the West-Asia conflict following the US midterm election results. Asian markets were mixed with traders rotating out of semiconductor shares into consumer and financial sectors, while Japan’s Nikkei 225 and KOSPI fell 0.39 per cent and 3.6 per cent respectively. Additionally, Bombay Coated & Special Steels is set to debut on exchanges on Thursday, and several companies including Aadhar Housing Finance and Bharti Airtel are
Lokesh meets global heads to seek investments and manufacturing centers in Andhra Pradesh across IT, medical devices, GCCs, and related sectors.
India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies.
Abbott India Ltd is quoting at Rs 26155, up 2.37% on the day as on 12:49 IST on the NSE. The stock is down 15.44% in last one year as compared to a 7.58% jump in NIFTY and a 18.39% jump in the Nifty Pharma index.
Indian regulators are intensifying scrutiny over misleading food product claims. Companies now face legal challenges for unsubstantiated marketing statements. New front-of-pack warning labels are proposed for unhealthy packaged foods. This regulatory push aims to provide consumers with clearer product information. Companies are consequently allocating more resources towards compliance and quality checks.
Stocks of Astral, Lenskart, Tata Motors, IRCON and other companies will be in focus on Wednesday as these companies reported their June quarter earnings after market hours on Tuesday. Investors will also watch Asian Energy Services, Awfis Space Solutions, Balaji Telefilms and others, which are scheduled to announce their results tomorrow.
Comprehensive Section Breakdown for Abbott India
Strategic Vision: Develops, manufactures, and markets branded generic medicines in India.
• Focus on branded generic medicines tailored to the domestic healthcare market.
• Extensive nationwide distribution network.
• Specialized divisions targeting distinct therapeutic areas.
Category: Pharmaceuticals
Focuses on general medicine, including pain management, gastroenterology, and anti-infectives.
Category: Pharmaceuticals
Focuses on therapies for thyroid disorders, diabetes care, weight management, and urological health.
Category: Pharmaceuticals
Manages a specialized portfolio of psychiatric and neurological treatments.
Category: Pharmaceuticals
Focuses on specialized formulations for anesthesiology and neonatology utilized within hospital settings.
Core Thesis: The company tailors its clinical research, product formulations, and commercial strategies to address local healthcare needs within the domestic Indian market.
• Manufacturing and Supply Chain: Operates a main manufacturing facility in Goa and utilizes a network of third-party contract manufacturers for a diversified and scalable supply chain. • Distribution Network: Distributes products nationwide via an extensive network of clearing and forwarding agents, stockists, and retail pharmacies. • Therapeutic Area Focus: Maintains a strong portfolio across Women's Health, Gastroenterology, Cardiology and Cardio-Metabolics, and Vaccines and Anti-Infectives.